Table 3 Characteristics of patients in the training cohort (n = 70)
Variable | Sen-group(n = 13) (n(%))/\(\bar {x} \pm s\) | Res-group(n = 12) (n(%))/\(\bar {x} \pm s\) | p | |
|---|---|---|---|---|
HE4(pmol/L) | 451.23 ± 414.143 | 849.73 ± 563.42 | 0.054 | |
Maximum tumor diameter | ≤ 5 cm | 2(15.4) | 3(25.0) | 0.0548 |
> 5 cm | 11(84.6) | 9(75.0) | ||
Vascular cancer thrombus | no | 11(84.6) | 8(66.7) | 0.294 |
yes | 2(15.4) | 4(33.3) | ||
Ascites cancer cell | no | 9(69.2) | 2(16.7) | 0.011 |
yes | 4(30.8) | 10(83.3) | ||
Neoadjuvant chemotherapy | no | 11(84.6) | 5(41.7) | 0.025 |
yes | 2(15.4) | 7(58.3) | ||
IL-6 IHC score | 0 | 11(84.6) | 4(33.3) | 0.008 |
1+ | 2(15.4) | 6(50.0) | ||
2+ | 0(0.0) | 2(16.7) | ||
CXCL1 IHC score | 0 | 11(84.6) | 6(50.0) | 0.062 |
1+ | 2(15.4) | 5(41.7) | ||
2+ | 0(0.0) | 1(8.3) | ||
CXCL2 IHC score | 0 | 11(84.6) | 5(41.7) | 0.023 |
1+ | 2(15.4) | 5(41.7) | ||
2+ | 0(0.0) | 2(16.7) | ||
ABCC1 IHC score | 0 | 11(84.6) | 6(50.0) | 0.069 |
1+ | 2(15.4) | 6(50.0) | ||
LRP IHC score | 0 | 10(76.9) | 3(25.0) | 0.008 |
1+ | 3(23.1) | 7(58.3) | ||
2+ | 0(0) | 2(16.7) | ||
BCL2 IHC score | 0 | 12(92.3) | 4(33.3) | 0.003 |
1+ | 1(7.7) | 6(50.0) | ||
2+ | 0(0.0) | 2(16.7) | ||